2021 Editor's Choice

January 2021

March 2021

May 2021

Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic

How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?

10 Years of End-of-Life Criteria in the United Kingdom

A Head-to-Head Comparison of the Standard Quality-Adjusted Life Year Model With the Annual Profile Model

Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA’s Health Technology Assessments

June 2021

Valuing Cures: Not If, But When?

Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports

Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations

Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a “Shared Savings” Approach to Cost Offsets

The Unfolding Method to Explore Health-Related Quality of Life Constructs in a Chinese General Population

Methods Used to Identify, Test, and Assess Impact on Preferences of Bolt-Ons: A Systematic Review

July 2021

Catalog of Age- and Medical Condition—Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis

“Looking Under the Hood” of Anchor-Based Assessment of Clinically Important Change: A Machine Learning Approach

Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare

Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies

August 2021

Indirect Economic Burden of Sickle Cell Disease

Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials

The CAPACITI Decision-Support Tool for National Immunization Programs

Development and Validation of an Instrument to Measure Health-Related Out-of-Pocket Costs: The Cost for Patients Questionnaire

Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression Analysis

September 2021

Mapping EQ-5D-3L to EQ-5D-5L

Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs

Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?

To What Extent Do Patient Preferences Differ From General Population Preferences

October 2021

How to Prevent Vaccines Falling Victim to Their Own Success: Inter-Temporal Dependency of Incidence Levels on Indirect Effects in Economic Re-Evaluations

Cost Effectiveness Analysis of Branded Drugs with Market Demand and Insurance

Towards better data dashboards for US drug value assessments

Quantifying Value of Hope

How Much Is a Human Life Worth? A Systematic Review

November 2021

Cost-effectiveness of COVID-19 Policy Measures: a Systematic Review

Will Americans Get Vaccinated? Predicting COVID-19 Vaccine Uptake Rates under Contingent Scenarios

Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations

The Extrapolation Performance of Survival Models for Data With A Cure Fraction: A Simulation Study

December 2021

Investigating Trends in The Quality of Reporting Of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 And 2019

A Review of Current Approaches to Defining and Valuing Innovation Ii Health Technology Assessment (HTA)

Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on Clinicaltrials.Gov

Antimicrobial Resistance: Is Health Technology Assessment Part of The Solution or Part of the Problem?